LuLISA: Feasibility Study of a New Immunoglobulin E (IgE) Assay Method

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT04751760
Collaborator
(none)
1,376
2
32.6
688
21.1

Study Details

Study Description

Brief Summary

The main objective is to study the feasibility of a new specific IgE assay using a bioluminescence technique in a pediatric and adult allergic population. For this, we will collect blood, and urine during a blood test scheduled for the follow-up of the patient.

Condition or Disease Intervention/Treatment Phase
  • Biological: collection of blood and urine

Detailed Description

Allergy is a raising public health problem. Specific IgE assays are useful tools to investigate the physiopathology of allergies. This method is achieved mainly by the ImmunoCAP enzyme immunoassay technique. This is an expensive test that requires a significant amount of blood. This is a limitation particularly in children. The time to get the results is long and a second consultation has to be scheduled in order to communicate the results to the patients. The main objective of this study is to assess the feasibility of a new specific IgE assay, named LuLISA, using a bioluminescence technique in urine and blood samples from pediatric and adult allergic population. This technique was recently published for the quantification of IgE against two peanut allergens and needs to be extended for the detection of other major allergens. A secondary objective is the evaluation of the time needed to obtain results.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1376 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Feasibility Study of a New Immunoglobulin E (IgE) Assay Method in Urine and Blood
Actual Study Start Date :
Apr 20, 2021
Anticipated Primary Completion Date :
Jan 7, 2024
Anticipated Study Completion Date :
Jan 7, 2024

Arms and Interventions

Arm Intervention/Treatment
People with sensitization or allergy

blood and urine will be collected during a blood test scheduled for the follow-up of the patient

Biological: collection of blood and urine
blood and urine will be collected during a blood test scheduled for the follow-up of the patient

Outcome Measures

Primary Outcome Measures

  1. Estimation of the the correlation of specific IgE concentrations for a given allergen analyzed using two different methods [Day 0]

    specific IgE concentrations for a given allergen will be measured by both LuLISA and ImmunoCAP and the results will be compared

Secondary Outcome Measures

  1. To study the correlation between the results of specific serum and urinary IgE dosages by LuLISA [Day 0]

    specific IgE concentrations for a given allergen will be measured in the sera and the urine from the same patient and the results will be compared

  2. To study the correlation between the results of specific IgE dosages in the venous blood and the capillary blood [Day 0]

    specific IgE concentrations for a given allergen will be measured in the venous blood and the capillary blood from the same patient and the results will be compared

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Months to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males or females 6 months' old or older

  • Sensitization or allergy towards a trophallergen, an aeroallergen, hymenoptera venom or drug proven by:

  • positive skin test (s)

  • and / or IgE specific (s)> 0.1 kUA / L

  • and / or anamnesis in favor of an allergic reaction of mediated IgE

  • Social coverage up to date

Exclusion Criteria:
  • Children younger than 6 months'old

  • Children's weight less than 10 kg

  • Pregnant or breastfeeding women

  • Patients with cystic fibrosis

  • Patients with dysimmune or autoimmune pathology

  • Anamnesis in favor of a delayed allergy or a contact allergy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Toulouse France 31000
2 Larrey hospital Toulouse France 31059

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Marine Michelet, MD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT04751760
Other Study ID Numbers:
  • RC31/20/0293
First Posted:
Feb 12, 2021
Last Update Posted:
May 18, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 18, 2022